The FDA plans to add aging and longevity to topics highlighted in its updated Focus Areas of Regulatory Science (FARS) report, according to remarks by FDA Chief Scientist Steven Kozlowski at the Aging Research & Drug Discovery Meeting. The updated FARS is expected early in fiscal 2027, with no specific publication date provided. Kozlowski emphasized the need for regulatory-accepted, pre-competitive endpoints that could support feasible clinical trial designs across aging-related conditions. Acting Chief of Staff Lowell M. Zeta framed the move as an inflection point for how FDA adapts to evolving science. In parallel, the FDA indicated it is working to establish shared endpoints that can serve as a bridge between biological and clinical measurement approaches, potentially shaping how developers design and justify trials in longevity and healthspan programs.